Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,281,344
  • Shares Outstanding, K 192,709
  • Annual Sales, $ 221,900 K
  • Annual Income, $ -535,760 K
  • EBIT $ -610 M
  • EBITDA $ -604 M
  • 60-Month Beta 1.13
  • Price/Sales 34.33
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 79.42% (-0.88%)
  • Historical Volatility 60.71%
  • IV Percentile 99%
  • IV Rank 97.91%
  • IV High 80.30% on 02/05/26
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 14) 13.57 (19.95%)
  • Put/Call Vol Ratio 3.41
  • Today's Volume 6,617
  • Volume Avg (30-Day) 2,066
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 49,931
  • Open Int (30-Day) 53,996
  • Expected Range 54.48 to 81.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 10
  • High Estimate -0.53
  • Low Estimate -1.24
  • Prior Year -1.31
  • Growth Rate Est. (year over year) +43.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.84 +8.29%
on 02/05/26
81.32 -16.32%
on 01/22/26
-5.94 (-8.03%)
since 01/06/26
3-Month
60.55 +12.39%
on 11/07/25
81.32 -16.32%
on 01/22/26
+5.32 (+8.48%)
since 11/06/25
52-Week
28.33 +140.20%
on 04/09/25
81.32 -16.32%
on 01/22/26
+35.35 (+108.10%)
since 02/06/25

Most Recent Stories

More News
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first...

BBIO : 68.05 (+6.78%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 68.05 (+6.78%)
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturity Offering priced at 0.75% interest rate and 45% conversion premium PALO...

BBIO : 68.05 (+6.78%)
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) --...

BBIO : 68.05 (+6.78%)
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

-  Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice...

BBIO : 68.05 (+6.78%)
BridgeBio to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 68.05 (+6.78%)
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 68.05 (+6.78%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,...

BBIO : 68.05 (+6.78%)
This Hot Biotech Stock Just Set New All-Time Highs

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to...

BBIO : 68.05 (+6.78%)
Is Moderna Stock Underperforming the Nasdaq?

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

$NASX : 23,031.21 (+2.18%)
BBIO : 68.05 (+6.78%)
MRNA : 41.01 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 72.96
2nd Resistance Point 71.80
1st Resistance Point 69.92
Last Price 68.05
1st Support Level 66.88
2nd Support Level 65.72
3rd Support Level 63.84

See More

52-Week High 81.32
Last Price 68.05
Fibonacci 61.8% 61.08
Fibonacci 50% 54.83
Fibonacci 38.2% 48.57
52-Week Low 28.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar